What is OncoCyte Corporation (OCX)?

OncoCyte Corporation (OCX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of OCX?

The current price of OCX is $3.20. Prices are updated in real time on Stocks360.

What is OCX's price-to-earnings (PE) ratio?

OCX's trailing twelve-month PE ratio is -2.15, based on current price and earnings per share data available on Stocks360.

What is OCX's market capitalization?

OCX's market capitalization is $91,517,760.00, placing it in the small-cap tier.

OncoCyte Corporation (OCX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.20

Market Cap

$91.52M

PE (TTM)

-2.15

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.99

Day Range

$2.82 – $3.20

52-wk Range

$1.92 – $4.75

Avg Volume

N/A

Volume

100.56K

OncoCyte Corporation (OCX) is a publicly traded company in the Healthcare sector. Latest price: $3.20. Market cap $91.52M. Trailing PE -2.15. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 6, 2025

EPS $-0.30 vs est. $-0.24

Missed by $0.06

Proprietary Signals

Signal snapshot temporarily unavailable.

About OncoCyte Corporation

OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.15×
P/S (TTM)	54.80×
P/B	-5.52×
P/FCF (TTM)	-3.56×
EV / EBITDA	-3.74×
EV / Sales	45.74×
Earnings Yield	-41.97%
Free Cash Flow Yield	-28.07%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$76.39M
Revenue (TTM)	$1.67M
Net Income (TTM)	-$38.41M
Free Cash Flow (TTM)	-$25.73M
Net Debt	-$15.13M
Working Capital	$10.26M
Gross Margin	47.60%
Operating Margin	-3011.86%
Net Margin	-2955.63%
Return on Equity	271.76%
Return on Invested Capital	-241.04%